168 related articles for article (PubMed ID: 24030928)
1. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
Frassetto L; Floren L; Barin B; Browne M; Wolfe A; Roland M; Stock P; Carlson L; Christians U; Benet L
Biopharm Drug Dispos; 2013 Nov; 34(8):442-51. PubMed ID: 24030928
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.
Frassetto LA; Browne M; Cheng A; Wolfe AR; Roland ME; Stock PG; Carlson L; Benet LZ
Am J Transplant; 2007 Dec; 7(12):2816-20. PubMed ID: 17949460
[TBL] [Abstract][Full Text] [Related]
3. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.
Frassetto LA; Tan-Tam CC; Barin B; Browne M; Wolfe AR; Stock PG; Roland M; Benet LZ
Transplantation; 2014 Mar; 97(6):702-7. PubMed ID: 24389906
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.
Frassetto L; Baluom M; Jacobsen W; Christians U; Roland ME; Stock PG; Carlson L; Benet LZ
Transplantation; 2005 Jul; 80(1):13-7. PubMed ID: 16003227
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
6. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
[TBL] [Abstract][Full Text] [Related]
10. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Takuva S; Evans D; Zuma K; Okello V; Louwagie G
Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
[TBL] [Abstract][Full Text] [Related]
11. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
Zaltzman JS
Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Barrail-Tran A; Goldwirt L; Gelé T; Laforest C; Lavenu A; Danjou H; Radenne S; Leroy V; Houssel-Debry P; Duvoux C; Kamar N; De Ledinghen V; Canva V; Conti F; Durand F; D'Alteroche L; Botta-Fridlund D; Moreno C; Cagnot C; Samuel D; Fougerou-Leurent C; Pageaux GP; Duclos-Vallée JC; Taburet AM; Coilly A
Eur J Clin Pharmacol; 2019 Nov; 75(11):1555-1563. PubMed ID: 31384986
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
[TBL] [Abstract][Full Text] [Related]
14. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Bartelink IH; Savic RM; Dorsey G; Ruel T; Gingrich D; Scherpbier HJ; Capparelli E; Jullien V; Young SL; Achan J; Plenty A; Charlebois E; Kamya M; Havlir D; Aweeka F
Pediatr Infect Dis J; 2015 Mar; 34(3):e63-70. PubMed ID: 25742090
[TBL] [Abstract][Full Text] [Related]
15. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
[TBL] [Abstract][Full Text] [Related]
16. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
18. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Teicher E; Vincent I; Bonhomme-Faivre L; Abbara C; Barrail A; Boissonnas A; Duclos-Vallée JC; Taburet AM; Samuel D; Vittecoq D
Clin Pharmacokinet; 2007; 46(11):941-52. PubMed ID: 17922559
[TBL] [Abstract][Full Text] [Related]
19. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
20. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
